Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States, impacting approximately 700,000 people each year. While medications exist to prevent the development of disease, they are associated with side effects, suggesting the need for new drugs that can be safely used to prevent it.
Novel drug, NFX-179, found to inhibit MEK activity, prevent cutaneous squamous cell carcinoma development
Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States, impacting approximately 700,000 people each year. While medications exist to prevent the development of disease, they are associated with side effects, suggesting the need for new drugs that can be safely used to prevent it.